JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Survival Benefit of Adjuvant Treatment with Huaier Granules Plus Lenvatinib in Hepatocellular Carcinoma Patients with Tumors Greater Than 5 cm After Radical Hepatectomy

  • 0Hepatic and Liver Transplantation Division, Department of Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Journal of Hepatocellular Carcinoma +

|

July 28, 2025

|

July 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Adjuvant therapy with Huaier granules and lenvatinib shows promise for improving outcomes in hepatocellular carcinoma (HCC) patients with high recurrence risk after surgery. Combination therapy significantly enhances overall and disease-free survival.

Area Of Science

  • Hepatobiliary Surgery
  • Oncology
  • Pharmacology

Background

  • Postoperative recurrence of hepatocellular carcinoma (HCC) significantly impacts long-term prognosis.
  • Microvascular invasion (MVI) is a key factor influencing HCC recurrence.
  • Identifying effective adjuvant treatments for high-risk HCC patients post-resection is crucial.

Purpose Of The Study

  • To investigate the efficacy of adjuvant treatment strategies for HCC patients with multiple recurrence factors after radical resection.
  • To evaluate the impact of Huaier granules and lenvatinib, alone or in combination, on patient outcomes.

Main Methods

  • Retrospective analysis of 243 HCC patients with high recurrence factors.
  • Comparison of outcomes between patients receiving adjuvant therapy (Huaier granules, lenvatinib, or both) and those receiving no adjuvant therapy.
  • Survival analysis including overall survival (OS) and disease-free survival (DFS).

Main Results

  • Adjuvant Huaier granules and lenvatinib monotherapy groups showed favorable prognoses (P < 0.05).
  • Combination therapy significantly improved OS (P = 0.001) and DFS (P = 0.001) compared to monotherapy.
  • Multivariate analysis identified Huaier granules combined with lenvatinib as an independent protective factor for OS (HR=0.777) and DFS (HR=0.753).

Conclusions

  • Postoperative adjuvant therapy with Huaier granules and lenvatinib improves long-term prognosis in high-risk HCC patients.
  • Combination therapy offers superior survival benefits over monotherapy.
  • This combination represents a potential strategy to mitigate HCC recurrence after radical resection.

Keywords: